Chronic HMG-CoA Reductase Inhibitor Treatment Contributes to Dysglycemia by Up-Regulating Hepatic Gluconeogenesis through Autophagy Induction

被引：0
作者：
Wang, Hye Jin
Park, Jae Yeo
Choe, Eun Yeong
Kwon, Obin
Lee, Yong-Ho
Kim, Gyuri
Bae, Jaehyun
Park, Se Hee
Yun, Yu Jung
Yun, Mijin
Kim, Chul Hoon
Lee, Hyangkyu
Kim, Young Bum
Kang, Eun Seok
机构：
来源：
DIABETES | 2014年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1787-P
引用
收藏
页码：A461 / A461
页数：1
相关论文
共 50 条
[41]   The Effects of Combined Treatment with an HMG-CoA Reductase Inhibitor and PPARγ Agonist on the Activation of Rat Pancreatic Stellate Cells [J].
Lee, Beom Jae ;
Lee, Hong Sik ;
Kim, Chang Duck ;
Jung, Sung Woo ;
Seo, Yeon Seok ;
Kim, Yong Sik ;
Jeen, Yoon Tae ;
Chun, Hoon Jai ;
Um, Soon Ho ;
Lee, Sang Woo ;
Choi, Jai Hyun ;
Ryu, Ho Sang .
GUT AND LIVER, 2012, 6 (02) :262-269
[42]   Additive effects of another kind of HMG-CoA reductase inhibitor with different pharmacokinetics in the treatment of heterozygous familial hypercholesterolemia [J].
Nozue, T ;
Nohara, A ;
Higashikata, T ;
Inazu, A ;
Mabuchi, H ;
Kajinami, K ;
Koizumi, J .
ATHEROSCLEROSIS, 2000, 153 (02) :525-526
[43]   Angiotensin Converting Enzyme Inhibitor and HMG-CoA Reductase Inhibitor as Adjunct Treatment for Persons with HIV Infection: A Feasibility Randomized Trial [J].
Baker, Jason V. ;
Hullsiek, Kathleen Huppler ;
Prosser, Rachel ;
Duprez, Daniel ;
Grimm, Richard ;
Tracy, Russell P. ;
Rhame, Frank ;
Henry, Keith ;
Neaton, James D. .
PLOS ONE, 2012, 7 (10)
[44]   Pitavastatin, an HMG-CoA Reductase Inhibitor, Ameliorates Endothelial Function in Chronic Smokers (vol 74, pg 195, 2010) [J].
Yoshida, Osamu ;
Kondo, Takahisa ;
Kureishi-Bando, Yasuko ;
Sugiura, Tomonori ;
Maeda, Kengo ;
Okumura, Kenji ;
Murohara, Toyoaki .
CIRCULATION JOURNAL, 2010, 74 (02) :386-386
[45]   A NEW SYNTHESIS OF HMG-COA REDUCTASE INHIBITOR NK-104 THROUGH HYDROSILYLATION-CROSS COUPLING REACTION [J].
TAKAHASHI, K ;
MINAMI, T ;
OHARA, Y ;
HIYAMA, T .
TETRAHEDRON LETTERS, 1993, 34 (51) :8263-8266
[46]   Fluvastatin, HMG-CoA reductase inhibitor: Antiatherogenic profiles through its lipid-lowering-dependent and -independent actions [J].
Mitani, H ;
Kimura, M .
CARDIOVASCULAR DRUG REVIEWS, 2000, 18 (04) :284-303
[47]   Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment [J].
Pickin, DM ;
McCabe, CJ ;
Ramsay, LE ;
Payne, N ;
Haq, IU ;
Yeo, WW ;
Jackson, PR .
HEART, 1999, 82 (03) :325-332
[48]   INCREASED IN-VIVO PRODUCTION OF HDL AND APOA-I UNDER THE TREATMENT WITH HMG-COA REDUCTASE INHIBITOR PRAVASTATIN [J].
SCHAEFER, JR ;
STEINMETZ, A ;
SCHWEER, H ;
STRACKE, H ;
SEYBERTH, H ;
KAFFARNIK, H .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1994, :A216-A216
[49]   A COMPARISON OF LOVASTATIN, AN HMG-COA REDUCTASE INHIBITOR, WITH GEMFIBROZIL, A FIBRINIC ACID-DERIVATIVE, IN THE TREATMENT OF PATIENTS WITH DIABETIC DYSLIPIDEMIA [J].
BELL, DSH .
CLINICAL THERAPEUTICS, 1995, 17 (05) :901-910
[50]   Effect of combined treatment with an angiotensin II receptor antagonist and an HMG-CoA reductase inhibitor on atherosclerosis in genetically hyperlipidemic rabbits [J].
Kato, M ;
Sada, T ;
Mizuno, M ;
Kitayama, K ;
Inaba, T ;
Koike, H .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2005, 46 (04) :556-562
12345